First patients recruited for Resistell’s international clinical study08.03.2023
Resistell developed a device and a test method which reduces the time for antibiotic susceptibility tests (AST) from days to hours - enabling the world's fastest antibiograms. The study will provide crucial information for healthcare providers in their decision-making process for the treatment of patients with difficult-to-treat infections.
Resistell, a leader in phenotypic nano-motion technology for measuring living cells, announces the launch of an international, multisite clinical study, PHENOTECH-1. Site initiation visits in three hospitals involved have taken place and the first patients have already been recruited for the study.
The study will be conducted in Switzerland (Lausanne), Spain (Madrid), and Austria (Innsbruck) and is aimed at assessing the sensitivity, specificity, accuracy and time to result of the Resistell Phenotech device in testing the antibiotic susceptibility of Gram-negative bacteria, including E. coli and K. pneumoniae, to clinically relevant antibiotics.
The study, which is designed as a prospective, non-interventional, multi-center, single-arm study, will provide crucial information for healthcare providers in their decision-making process for the treatment of patients with difficult-to-treat infections.
“I am extremely excited to see the study up and running. I believe that the data we will collect will provide further proof that our unique nano-motion technology can help save lives and directly tackle one of the world’s largest unmet medical needs”, said the Co-founder and CEO of Resistell, Danuta Cichocka.